251 related articles for article (PubMed ID: 28093943)
1. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014.
Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):285-288. PubMed ID: 28093943
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
Rathi VK; Krumholz HM; Masoudi FA; Ross JS
JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
[TBL] [Abstract][Full Text] [Related]
3. US Food and Drug Administration Clearance of Moderate-Risk Otolaryngologic Devices via the 510(k) Process, 1997-2016.
Rathi VK; Gadkaree SK; Ross JS; Kozin ED; Sethi RK; Naunheim MR; Puram SV; Gray ST
Otolaryngol Head Neck Surg; 2017 Oct; 157(4):608-617. PubMed ID: 28786317
[TBL] [Abstract][Full Text] [Related]
4. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.
Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
Otolaryngol Head Neck Surg; 2017 Apr; 156(4):683-692. PubMed ID: 28116974
[TBL] [Abstract][Full Text] [Related]
5. Device Safety.
Rathi VK; Gray ST
Otolaryngol Clin North Am; 2019 Feb; 52(1):103-114. PubMed ID: 30245039
[TBL] [Abstract][Full Text] [Related]
6. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
7. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
8. Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration.
Rathi VK; Ross JS; Samuel AM; Mehra S
Otolaryngol Head Neck Surg; 2015 Sep; 153(3):400-8. PubMed ID: 26044785
[TBL] [Abstract][Full Text] [Related]
9. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
[TBL] [Abstract][Full Text] [Related]
10. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
[TBL] [Abstract][Full Text] [Related]
11. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.
Dhruva SS; Bero LA; Redberg RF
JAMA; 2009 Dec; 302(24):2679-85. PubMed ID: 20040556
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.
Zheng SY; Dhruva SS; Redberg RF
JAMA; 2017 Aug; 318(7):619-625. PubMed ID: 28810022
[TBL] [Abstract][Full Text] [Related]
13. Recalls of Moderate- and High-Risk Otolaryngologic Devices Approved by the US Food and Drug Administration, 2003-2019.
Talati IA; Parsa KM; Gao WZ
Otolaryngol Head Neck Surg; 2022 Nov; 167(5):832-838. PubMed ID: 35290135
[TBL] [Abstract][Full Text] [Related]
14. Transparency and Dermatologic Device Approval by the US Food and Drug Administration.
Ezaldein HH; Scott JF; Yin ES; Ventura A; DeRuyter NP; Leffell DJ
JAMA Dermatol; 2018 Mar; 154(3):273-280. PubMed ID: 29365020
[TBL] [Abstract][Full Text] [Related]
15. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
16. Radiological Medical Device Innovation: Approvals via the Premarket Approval Pathway From 2000 to 2015.
Ghobadi CW; Hayman EL; Finkle JH; Walter JR; Xu S
J Am Coll Radiol; 2017 Jan; 14(1):24-33. PubMed ID: 28061962
[TBL] [Abstract][Full Text] [Related]
17. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.
Rome BN; Kramer DB; Kesselheim AS
JAMA; 2014 Jan 22-29; 311(4):385-91. PubMed ID: 24449317
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
19. Medical devices: US medical device regulation.
Jarow JP; Baxley JH
Urol Oncol; 2015 Mar; 33(3):128-32. PubMed ID: 25458071
[TBL] [Abstract][Full Text] [Related]
20. Medical devices; exemptions from premarket notification and reserved devices; class I--FDA. Notice.
Fed Regist; 1998 Feb; 63(21):5387-93. PubMed ID: 10177333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
